Related Experiment Videos
Primary antiphospholipid syndrome and cardiovascular disease
V Ducceschi1, B Sarubbi, A Iacono
1Seconda Università degli Studi di Napoli, Italy.
European Heart Journal
|April 1, 1995
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Managing a Mental Disorder With New Technologies: TheLeadless Pacemaker in Reel's Syndrome, a Case Report.
Pacing and clinical electrophysiology : PACE·2024
Efficacy and safety of dabigatran in a "real-life" population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry.
European review for medical and pharmacological sciences·2015
[Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2013
Prolonged corrected QT dispersion.
Oncology reports·2011
Immunological risk identified by single-cell multi-omics and cardiovascular outcomes.
European heart journal·2026
RUNX1-driven endothelial-to-mesenchymal transition contributes to remodelling in LMNA cardiomyopathy.
European heart journal·2026
Endometriosis and long-term risk of venous thromboembolism: a Danish nationwide study.
European heart journal·2026